At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 711 enrolled
Drug / intervention
semaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating semaglutide, liraglutide, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 711 participants across 108 sites in 13 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesCroatia, Czechia, Germany, Hungary, Japan, Latvia, Poland, Puerto Rico, Slovakia, South Africa, Ukraine, United Arab Emirates, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionAug 2017
Study CompletionMar 2018
TodayJul 2026
First PostedAug 11, 2016
Enrollment StartAug 10, 2016
Primary CompletionAug 19, 2017
Study CompletionMar 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 9.9 years ago
Interventions
semaglutidedrug
Oral semaglutide once-daily.
liraglutidedrug
Subcutaneous (s.c.) injection once-daily.
placebodrug
Placebo once-daily.